Cardiovascular Effects of Salbutamol

Introduction to Cardiovascular Risks

The American Heart Association acknowledges that salbutamol increases heart rate, with an average increase of 9.1 beats/min (95% CI: 5.3-12.9) in patients using single doses of beta-2 agonists 1, 2

The use of metered dose inhalers (MDIs) causes significantly less tachycardia than nebulizers, with approximately 6.47 beats/min less increase (95% CI: -11.69 to -1.25), as noted by the American College of Cardiology 3
In patients with structural heart disease, 10 out of 18 COPD patients developed paroxysmal atrial fibrillation or supraventricular tachycardia with salbutamol, highlighting the need for caution in high-risk populations 1, 2

The American College of Cardiology recommends exercising caution in patients with underlying cardiac disease, as the heart rate increase can precipitate myocardial ischemia, with a relative risk of 2.54 (95% CI: 1.59-4.05) for adverse cardiovascular events in patients with atrial fibrillation 1, 2
Beta-2 agonists can induce and maintain existing atrial fibrillation, with a significant increase in adverse cardiovascular events, as reported by the European Society of Cardiology 1, 2

The American Heart Association notes that salbutamol can cause palpitations, premature ventricular contractions, hypertension, arrhythmias, and hypokalemia, which can predispose to arrhythmias, emphasizing the importance of using the lowest effective dose and preferring MDIs over nebulizers 3, 4
The Surviving Sepsis Campaign recommends against routine use of beta-agonists, including salbutamol, in sepsis-induced ARDS without specific indications like bronchospasm, due to increased heart rates and mortality in the BALTI-2 trial, as reported by the Society of Critical Care Medicine 6, 7